CSBTF logo

Kuros Biosciences AG (CSBTF) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Cotizando a $, Kuros Biosciences AG (CSBTF) es una empresa del sector Healthcare valorada en 0. La acción obtiene una puntuación de 57/100, una calificación moderada basada en 9 KPI cuantitativos.

Ultimo analisis: 17 mar 2026
Puntuación de IA de 57/100

Kuros Biosciences AG (CSBTF) Resumen de Asistencia Médica y Tuberías

CEOChristopher T. Fair
Empleados122
Sede CentralSchlieren, CH
Año de la oferta pública inicial (OPI)2014
IndustriaBiotechnology

Kuros Biosciences AG specializes in developing and commercializing biopharmaceutical products for tissue repair and bone regeneration, with a focus on orthobiologics and sealants. The company's pipeline targets significant unmet needs in orthopedics, spinal surgery, and neurosurgery, positioning it within the competitive biotechnology landscape.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 17 mar 2026

Tesis de Inversión

Kuros Biosciences AG presents a compelling investment thesis based on its innovative product pipeline and strategic focus on tissue repair and bone regeneration. With a market capitalization of $1.23 billion and a P/E ratio of 563.02, the company demonstrates significant growth potential. Key value drivers include the commercial success of MagnetOs products and the advancement of KUR-111 and KUR-113 through clinical trials. The company's collaboration with Checkmate Pharmaceuticals also adds potential upside. However, investors should be aware of the risks associated with clinical trial outcomes and regulatory approvals. The company's high gross margin of 87.0% indicates pricing power. The beta of 0.63 suggests lower volatility than the market.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • Market capitalization of $1.23 billion reflects investor confidence in Kuros Biosciences' growth potential.
  • A P/E ratio of 563.02 indicates high expectations for future earnings growth.
  • Gross margin of 87.0% demonstrates strong pricing power and efficient cost management.
  • Beta of 0.63 suggests lower volatility compared to the broader market.
  • The company's focus on tissue repair and bone regeneration addresses a significant market need in orthopedics, spinal surgery, and neurosurgery.

Competidores y Pares

Fortalezas

  • Innovative product pipeline targeting unmet clinical needs.
  • Strong gross margin indicating pricing power.
  • Established presence in key markets (US and EU).
  • Strategic partnerships and collaborations.

Debilidades

  • Reliance on successful clinical trial outcomes.
  • Dependence on regulatory approvals.
  • Limited product diversification.
  • OTC market trading may limit liquidity.

Catalizadores

  • Upcoming: Clinical trial results for KUR-111 in tibial plateau fractures (2027-2028).
  • Upcoming: Clinical trial results for KUR-113 in tibial shaft fractures and spinal interbody fusion (2027-2028).
  • Upcoming: Regulatory approval and commercial launch of Neuroseal in the EU and US (2026-2027).
  • Ongoing: Expansion of MagnetOs product line into new geographic markets.
  • Ongoing: Strategic partnerships and collaborations to expand product pipeline.

Riesgos

  • Potential: Unfavorable clinical trial results for KUR-111 and KUR-113.
  • Potential: Delays in regulatory approval for Neuroseal.
  • Potential: Competition from other biopharmaceutical companies.
  • Ongoing: Dependence on successful commercialization of existing products.
  • Ongoing: Risks associated with operating in the OTC market.

Oportunidades de crecimiento

  • Expansion of MagnetOs product line: Kuros Biosciences can expand the MagnetOs product line into new geographic markets and applications. The global orthobiologics market is projected to reach $7.9 billion by 2027, providing a significant opportunity for growth. Timeline: Ongoing.
  • Advancement of KUR-111 and KUR-113: Successful completion of clinical trials and regulatory approval for KUR-111 and KUR-113 would represent a major growth catalyst for Kuros Biosciences. These products target tibial plateau and tibial shaft fractures, respectively, addressing a significant unmet need in orthopedic surgery. Timeline: 2027-2028.
  • Commercialization of Neuroseal: The commercialization of Neuroseal, a synthetic tissue sealant for the prevention of cerebrospinal fluid leakage, represents another growth opportunity for Kuros Biosciences. The market for tissue sealants is growing, driven by increasing demand for minimally invasive surgical procedures. Timeline: 2026-2027.
  • Strategic partnerships and collaborations: Kuros Biosciences can pursue strategic partnerships and collaborations to expand its product pipeline and geographic reach. The collaboration with Checkmate Pharmaceuticals for the development of CYT003 demonstrates the company's commitment to this strategy. Timeline: Ongoing.
  • Acquisition of complementary technologies: Kuros Biosciences can acquire complementary technologies to strengthen its product portfolio and enhance its competitive position. This could include technologies related to biomaterials, drug delivery, or surgical techniques. Timeline: Opportunistic.

Oportunidades

  • Expansion into new geographic markets.
  • Development of new applications for existing products.
  • Acquisition of complementary technologies.
  • Increasing demand for minimally invasive surgical procedures.

Amenazas

  • Competition from other biopharmaceutical companies.
  • Changes in regulatory requirements.
  • Unfavorable clinical trial results.
  • Economic downturn affecting healthcare spending.

Ventajas competitivas

  • Proprietary technology and intellectual property.
  • Established distribution network in key markets.
  • Strong relationships with key opinion leaders.
  • Regulatory expertise and experience.

Acerca de CSBTF

Kuros Biosciences AG, headquartered in Schlieren, Switzerland, is a biopharmaceutical company dedicated to the development and commercialization of innovative products for tissue repair and bone regeneration. The company operates through three segments: Medical Devices, Pharmaceuticals, and Legacy Portfolio. Kuros Biosciences' story began with a vision to address unmet needs in orthopedics, spinal surgery, and neurosurgery through advanced biopharmaceutical solutions. Their lead products, MagnetOs Granules and MagnetOs Putty, are designed for orthopedic, spinal, and dental applications and are available in both the EU and the US. The company's pipeline also includes fibrin/PTH orthobiologics, such as KUR-111, which has completed Phase 2b clinical trials for tibial plateau fractures, and KUR-113, which has completed Phase 2b clinical trials for tibial shaft fractures and is in Phase II trials for spinal interbody fusion. Additionally, Kuros Biosciences is developing Neuroseal EU and US, a synthetic tissue sealant aimed at preventing cerebrospinal fluid leakage following cranial or spinal surgery. Kuros Biosciences also has a collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for oncology treatments. The company's strategic focus on innovation and partnerships positions it for continued growth in the biopharmaceutical sector.

Qué hacen

  • Develops and commercializes biopharmaceutical products.
  • Focuses on tissue repair and bone regeneration.
  • Offers orthobiologics pipeline products like MagnetOs Granules and MagnetOs Putty.
  • Develops fibrin/PTH orthobiologics such as KUR-111 and KUR-113.
  • Creates sealants pipeline products including Neuroseal EU and US.
  • Collaborates with other companies for oncology treatments.

Modelo de Negocio

  • Develops and commercializes proprietary biopharmaceutical products.
  • Generates revenue through product sales in the US, EU, and internationally.
  • Partners with other companies for collaborative development and commercialization.
  • Focuses on high-margin products in specialized therapeutic areas.

Contexto de la Industria

Kuros Biosciences AG operates within the biotechnology industry, which is characterized by rapid innovation and intense competition. The market for tissue repair and bone regeneration is driven by an aging population, increasing demand for minimally invasive surgical procedures, and advancements in biomaterials. Kuros Biosciences competes with other biopharmaceutical companies developing similar products, including ASCLF (Ascentage Pharma Group Corp), CHIZF (Chiesi Farmaceutici SpA), CSPHF (CASI Pharmaceuticals Inc), MEOBF (MeoVaccs), and NPPNY (Nippon Piston Ring Co Ltd). The company's success depends on its ability to develop and commercialize innovative products that address unmet clinical needs and gain regulatory approval.

Clientes Clave

  • Hospitals and surgical centers.
  • Orthopedic surgeons and neurosurgeons.
  • Dental professionals.
  • Patients requiring tissue repair and bone regeneration.
Confianza de la IA: 71% Actualizado: 17 mar 2026

Finanzas

Gráfico e información

Precio de la acción de Kuros Biosciences AG (CSBTF): Price data unavailable

Últimas noticias

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para CSBTF.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para CSBTF.

MoonshotScore

57/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de CSBTF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Clasificación

Sector Healthcare Industria Biotechnology

Últimas Noticias

Liderazgo: Christopher T. Fair

CEO

Christopher T. Fair serves as the CEO of Kuros Biosciences AG, leading a team of 122 employees. His background includes extensive experience in the biopharmaceutical industry, with a focus on commercialization and strategic development. Prior to joining Kuros, Mr. Fair held leadership positions at various pharmaceutical companies, where he was responsible for driving revenue growth and expanding market share. He brings a wealth of knowledge in product development, regulatory affairs, and business development to Kuros Biosciences.

Historial: Under Christopher T. Fair's leadership, Kuros Biosciences has focused on advancing its product pipeline and expanding its commercial presence. Key achievements include the successful commercialization of MagnetOs products and the advancement of KUR-111 and KUR-113 through clinical trials. He has also overseen the company's collaboration with Checkmate Pharmaceuticals, demonstrating his commitment to strategic partnerships.

Información del mercado OTC de CSBTF

The OTC Other tier represents the lowest tier of the OTC market, indicating that Kuros Biosciences AG (CSBTF) may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, and investors should exercise caution due to the potential for increased risk and volatility. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and may not be subject to the same level of scrutiny.

  • Nivel OTC: OTC Other
  • Estado de divulgación: Unknown
Liquidez: Liquidity for CSBTF on the OTC market is likely limited, which can result in wider bid-ask spreads and increased trading difficulty. Lower trading volumes may make it challenging to buy or sell shares quickly without significantly impacting the price. Investors should be aware of these liquidity constraints and consider them when evaluating the potential risks and rewards of investing in CSBTF.
Factores de riesgo OTC:
  • Limited financial disclosure increases the risk of investing in CSBTF.
  • Lower liquidity can lead to increased price volatility.
  • The OTC Other tier indicates a higher risk profile compared to companies listed on major exchanges.
  • Potential for fraud or manipulation is higher on the OTC market.
  • Lack of regulatory oversight can make it difficult to assess the company's legitimacy.
Lista de verificación de diligencia debida:
  • Verify the company's financial statements and SEC filings (if any).
  • Research the company's management team and their track record.
  • Assess the company's competitive landscape and market position.
  • Evaluate the company's product pipeline and potential for future growth.
  • Check for any legal or regulatory issues.
  • Consult with a financial advisor before investing.
  • Confirm the company's legitimacy and business operations.
Señales de legitimidad:
  • The company has a clear business model and revenue streams.
  • Kuros Biosciences AG has an established presence in the biopharmaceutical industry.
  • The company has a pipeline of products in development.
  • The company has strategic partnerships and collaborations.
  • The company has a management team with relevant experience.

CSBTF Preguntas Frecuentes sobre Acciones de Healthcare

¿Cuáles son los factores clave para evaluar CSBTF?

Kuros Biosciences AG (CSBTF) actualmente tiene una puntuación IA de 57/100, indicando puntuación moderada. Fortaleza clave: Innovative product pipeline targeting unmet clinical needs.. Riesgo principal a monitorear: Potential: Unfavorable clinical trial results for KUR-111 and KUR-113.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de CSBTF?

CSBTF actualmente puntúa 57/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de CSBTF?

Los precios de CSBTF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre CSBTF?

La cobertura de analistas para CSBTF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en CSBTF?

Las categorías de riesgo para CSBTF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Unfavorable clinical trial results for KUR-111 and KUR-113.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de CSBTF?

La relación P/E para CSBTF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está CSBTF sobrevalorada o infravalorada?

Determinar si Kuros Biosciences AG (CSBTF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de CSBTF?

Kuros Biosciences AG (CSBTF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • AI analysis is pending for CSBTF, so some information may be incomplete.
  • OTC market data may be less reliable than data for exchange-listed companies.
Fuentes de datos

Popular Stocks